Nervous Disorder TRIZ Cases

Humanized antibodies bind P-selectin with high affinity, blocking leukocyte adhesion and improving microcirculatory flow in inflammatory diseases.

Bacteroides probiotics modulate the gut-brain axis to resolve ineffective behavioral symptom management in autism spectrum disorder patients.

Catabolic enzymes break down amyloid fibrils using antibody intermediaries for targeted delivery.

A multi-marker panel detects multiple sclerosis relapses using urokinase plasminogen activator and kallikrein levels.

PPARα agonists activate receptor pathways to increase allopregnanolone levels, addressing inadequate treatment effectiveness in neuropsychiatric disorders.

Viral vectors deliver STXBP1 gene constructs to restore protein function and treat neurodevelopmental disorders.

Dextran-coated carbon nanotubes selectively target inflammatory cells via scavenger receptors, resolving non-specific tissue damage during photothermal therapy.

Minor cannabinoid compositions modulate central sensitization biomarkers to reduce migraine and fibromyalgia pain while minimizing THC side effects.

Replaces expensive DDQ reagents with NaH and CH3I to synthesize (7-methoxy-1-naphthyl)acetonitrile from 7-methoxy-1-naphthoic acid, lowering costs.

Modified anti-Siglec-7 antibodies reduce effector function through specific amino acid substitutions in the Fc region.

Monoclonal antibody binds phosphorylated Tau serine 422 to resolve cross-reactivity issues in Tauopathy treatment.

D9-caffeine extends half-life and minimizes adverse effects by slowing cytochrome P450 demethylation.

An albumin-cisplatin conjugate delivers cisplatin to glioma cells via human serum albumin.

Aryl and heteroaryl compounds stabilize the galactocerebrosidase enzyme, reducing substrate accumulation in lysosomal storage diseases.

Developing specific crystalline forms A and B resolves the contradiction between biological activity and composition stability in chronic pain treatments.

A recombinant protein combining HSP65 and MOG35-55 epitopes induces immune tolerance to prevent multiple sclerosis.

Isolating 6-hydroxy cannabidivarin resolves composition complexity and poor bioavailability in crude cannabis extracts.

Compounds inhibit autotaxin and alter lymphocyte trafficking to prevent disability progression in multiple sclerosis.

Structural modifications of capsaicin reduce pungency and side effects, enabling higher dosing for effective pain relief and cancer treatment.

Non-ketogenic booster composition containing C4 and C6 fatty acids enhances ketone production for dietary supplementation.

Chiral acid resolution of aryl hydrazine intermediates achieves high enantiomeric purity and yield without exhaustive purification.

A Sceletium extract combined with an activity enhancer boosts PDE4 inhibition through synergistic phytochemical interactions.

Compound I modulates histamine receptors to improve wakefulness and cognitive function while maintaining a favorable safety profile compared to modafinil.

High-dose alpha-1 antitrypsin extends the therapeutic window beyond narrow rtPA limits to prevent neurodegeneration.

Antibodies target IL-17A, IL-17F, and the heterodimeric complex to inhibit pro-inflammatory cytokine production in autoimmune diseases.

PEGylated exenatide inhibits pathological microglial activation, reducing pro-inflammatory cytokines to reverse cognitive deficits from viral infections.

Unbalanced triple reuptake inhibitor compound targets norepinephrine circuitries.

An AAV vector with an AAT promoter provides sustained porphobilinogen deaminase expression to alleviate acute intermittent porphyria symptoms.

Hydrophobic modifications to prominin-1 peptides increase VEGF binding activity, addressing insufficient pro-angiogenic effects in current therapeutic methods.

Small molecule chaperones bind to beta-glucocerebrosidase to restore enzymatic activity, clearing protein aggregates without complex replacement therapy.

A chiral synthetic approach establishes enantiomeric purity during early synthesis stages for a gamma-secretase modulator compound.

Specific laminin isoforms maintain multipotency during expansion, resolving the contradiction between cell productivity and composition stability.

Modified humanized antibodies restore binding activity to N-terminal truncated amyloid peptides through specific variable domain mutations.

Hydrolyzed hen egg lysozyme produces water-soluble peptides with high Trp/LNAA ratios, bypassing regulatory limits on free tryptogen supplements.

Ultrasonic nanonization creates stable CBD suspensions that bypass stratum corneum entrapment to enhance transdermal bioavailability.

A fusion protein links a TNF superfamily ligand to a collectin trimerization domain to form stable oligomeric complexes.

Agitating carbetocin solutions with polysorbates filters aggregates, maintaining stability and uniformity.

Retrograde protein kinase G transport modulates pain gene expression, treating primary hyperalgesia by targeting the peripheral nervous system origin.

Oral GTβHB maintains plasma ketone bodies between 2 and 7 mM, reducing cumulative neuronal deficits following transient ischemic attacks.

TrkB ligand conjugates target frontal cortex cells, reducing off-target effects.

Aldehyde-linked quaternary ammonium salts reduce solubility to prevent dose dumping and ensure stable delivery across varying pH environments.

AAV-mediated XBP1s overexpression enhances neuronal proteostasis and delays symptomatic onset in amyotrophic lateral sclerosis models.

Antagonist antibodies block IL-7R signaling to treat diabetes and autoimmune disorders while resolving uncertainty about required in vivo properties.

Fusion proteins engage the Hsp70 chaperone mechanism to reduce mutant TDP-43 aggregation and prevent neurodegenerative disease progression.

Segmented signaling protocol directs stem cells into proprioceptors, resolving specificity bottlenecks for neurodegenerative disease treatments.

Conjugated penetration enhancers transport antigen-binding polypeptides across the blood-brain barrier, resolving small molecule delivery limits.